References
1. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni
I, et al. Consensus statement on the definition of orthostatic
hypotension, neurally mediated syncope and the postural tachycardia
syndrome. Clinical Autonomic Research. 2011;21(2):69-72.
2. Poon IO, Braun U. High prevalence of orthostatic hypotension and its
correlation with potentially causative medications among elderly
veterans. Journal of Clinical Pharmacy and Therapeutics.
2005;30(2):173-8.
3. Metzler M, Duerr S, Granata R, Krismer F, Robertson D, Wenning GK.
Neurogenic orthostatic hypotension: pathophysiology, evaluation, and
management. J Neurol. 2013;260(9):2212-9.
4. Ricci F, De Caterina R, Fedorowski A. Orthostatic Hypotension:
Epidemiology, Prognosis, and Treatment. J Am Coll Cardiol.
2015;66(7):848-60.
5. Weiss A, Grossman E, Beloosesky Y, Grinblat J. Orthostatic
Hypotension in Acute Geriatric Ward: Is It a Consistent Finding?
Archives of Internal Medicine. 2002;162(20):2369-74.
6. Rose Kathryn M, Eigenbrodt Marsha L, Biga Rebecca L, Couper David J,
Light Kathleen C, Sharrett AR, et al. Orthostatic Hypotension Predicts
Mortality in Middle-Aged Adults. Circulation. 2006;114(7):630-6.
7. Eschlböck S, Wenning G, Fanciulli A. Evidence-based treatment of
neurogenic orthostatic hypotension and related symptoms. J Neural Transm
(Vienna). 2017;124(12):1567-605.
8. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The
Orthostatic Hypotension Questionnaire (OHQ): validation of a novel
symptom assessment scale. Clin Auton Res. 2012;22(2):79-90.
9. Busner J, Targum SD. The clinical global impressions scale: applying
a research tool in clinical practice. Psychiatry (Edgmont).
2007;4(7):28-37.
10. BNF. British National Formulary (BNF): NICE; 2022 [Available from:
https://bnf.nice.org.uk.
11. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P,
et al. DrugBank: a comprehensive resource for in silico drug discovery
and exploration. Nucleic Acids Res. 2006;34(Database issue):D668-72.
12. Byun JI, Kim DY, Moon J, Shin HR, Sunwoo JS, Lee WJ, et al. Efficacy
of atomoxetine versus midodrine for neurogenic orthostatic hypotension.
Annals of clinical and translational neurology. 2020;7(1):112‐20.
13. Okamoto LE, Shibao C, Gamboa A, Choi L, Diedrich A, Raj SR, et al.
Synergistic effect of norepinephrine transporter blockade and alpha-2
antagonism on blood pressure in autonomic failure. Hypertension.
2012;59(3):650-6.
14. Okamoto LE, Shibao CA, Gamboa A, Diedrich A, Raj SR, Black BK, et
al. Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in
Patients With Neurogenic Orthostatic Hypotension. Hypertension.
2019;73(1):235-41.
15. Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, et
al. Efficacy of atomoxetine versus midodrine for the treatment of
orthostatic hypotension in autonomic failure. Hypertension.
2014;64(6):1235-40.
16. Byun JI, Moon J, Kim DY, Shin H, Sunwoo JS, Lim JA, et al. Efficacy
of single or combined midodrine and pyridostigmine in orthostatic
hypotension. Neurology. 2017;89(10):1078‐86.
17. Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH,
et al. Neurogenic orthostatic hypotension: a double-blind,
placebo-controlled study with midodrine. American Journal of Medicine.
1993;95(1):38-48.
18. Kaufmann H, Saadia D, Voustianiouk A. Midodrine in neurally mediated
syncope: a double-blind, randomized, crossover study. Annals of
Neurology. 2002;52(3):342-5.
19. Low PA, Gilden JL, Freeman R, Sheng K-N, McElligott MA. Efficacy of
Midodrine vs Placebo in Neurogenic Orthostatic Hypotension: A
Randomized, Double-blind Multicenter Study. JAMA. 1997;277(13):1046-51.
20. Smith W, Wan H, Much D, Robinson AG, Martin P. Clinical benefit of
midodrine hydrochloride in symptomatic orthostatic hypotension: a phase
4, double-blind, placebo-controlled, randomized, tilt-table study.
Clinical Autonomic Research. 2016;26(4):269-77.
21. Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA,
Sheng KN, et al. A double-blind, dose-response study of midodrine in
neurogenic orthostatic hypotension. Neurology. 1998;51(1):120-4.
22. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with
neurogenic orthostatic hypotension associated with Parkinson’s disease
(NOH306A). J Parkinsons Dis. 2014;4(1):57-65.
23. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for
the Short-Term Treatment of Symptomatic Neurogenic Orthostatic
Hypotension in Parkinson’s Disease (nOH306B). Movement Disorders.
2015;30(5):646-54.
24. Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ. Safety and
Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in
Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
Journal of Parkinson’s Disease. 2016;6(4):751-9.
25. Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr
MD, et al. Norepinephrine precursor therapy in neurogenic orthostatic
hypotension. Circulation. 2003;108(6):724-8.
26. Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines
S, et al. Pyridostigmine treatment trial in neurogenic orthostatic
hypotension. Archives of Neurology. 2006;63(4):513-8.
27. Shibao C, Okamoto LE, Gamboa A, Yu C, Diedrich A, Raj SR, et al.
Comparative efficacy of yohimbine against pyridostigmine for the
treatment of orthostatic hypotension in autonomic failure. Hypertension.
2010;56(5):847-51.
28. Arnold AC, Ramirez CE, Choi L, Okamoto LE, Gamboa A, Diedrich A, et
al. Combination ergotamine and caffeine improves seated blood pressure
and presyncopal symptoms in autonomic failure. Frontiers in Physiology.
2014;5 JUN (no pagination).
29. Senard JM, Rascol O, Rascol A, Montastruc JL. Lack of yohimbine
effect on ambulatory blood pressure recording: a double-blind cross-over
trial in parkinsonians with orthostatic hypotension. Fundamental &
Clinical Pharmacology. 1993;7(8):465-70.
30. Schoffer KL, Henderson RD, O’Maley K, O’Sullivan JD.
Nonpharmacological treatment, fludrocortisone, and domperidone for
orthostatic hypotension in Parkinson’s disease. Movement Disorders.
2007;22(11):1543-9.
31. Campbell IW, Ewing DJ, Clarke BF. Therapeutic experience with
fludrocortisone in diabetic postural hypotension. British medical
journal. 1976;1(6014):872-4.
32. Rowe PC, Calkins H, DeBusk K, McKenzie R, Anand R, Sharma G, et al.
Fludrocortisone acetate to treat neurally mediated hypotension in
chronic fatigue syndrome: a randomized controlled trial. Jama.
2001;285(1):52-9.
33. Schreglmann SR, Büchele F, Sommerauer M, Epprecht L, Kägi G,
Hägele-Link S, et al. Pyridostigmine bromide versus fludrocortisone in
the treatment of orthostatic hypotension in Parkinson’s disease - a
randomized controlled trial. Eur J Neurol. 2017;24(4):545-51.
34. Bacchi S, Chim I, Kramer P, Postuma RB. Domperidone for Hypotension
in Parkinson’s Disease: A Systematic Review. Journal of Parkinson’s
Disease. 2017;7(4):603-17.
35. Elgebaly A, Abdelazeim B, Mattar O, Gadelkarim M, Salah R, Negida A.
Meta-analysis of the safety and efficacy of droxidopa for neurogenic
orthostatic hypotension. Clinical Autonomic Research. 2016;26(3):171-80.
36. Izcovich A, Gonzalez Malla C, Manzotti M, Catalano HN, Guyatt G.
Midodrine for orthostatic hypotension and recurrent reflex syncope: A
systematic review. Neurology. 2014;83(13):1170-7.
37. Logan IC, Witham MD. Efficacy of treatments for orthostatic
hypotension: a systematic review. Age Ageing. 2012;41(5):587-94.
38. Ong AC, Myint PK, Shepstone L, Potter JF. A systematic review of the
pharmacological management of orthostatic hypotension. Int J Clin Pract.
2013;67(7):633-46.
39. Veazie S, Peterson K, Ansari Y, Chung KA, Gibbons CH, Raj SR, et al.
Fludrocortisone for orthostatic hypotension. Cochrane Database of
Systematic Reviews. 2021(5).
40. Watson G. CONtrol, Fludrocortisone OR Midodrine for the treatment of
Orthostatic Hypotension (CONFORM-OH): a randomised controlled trial.
2021.
41. Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et
al. Droxidopa for neurogenic orthostatic hypotension. A randomized,
placebo-controlled, phase 3 trial. 2014;83(4):328-35.
42. Campbell IW, Ewing DJ, Clarke BF. 9-Alpha-fluorohydrocortisone in
the treatment of postural hypotension in diabetic autonomic neuropathy.
Diabetes. 1975;24(4):381-4.